Skipping breast surgery after successful drug treatment
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests whether some women with a specific type of early breast cancer can safely avoid surgery if their tumor disappears completely after targeted drug therapy. The treatment uses medicines that target HER2-positive cancer cells, and the goal is to reduce the need for invasive procedures.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 40 or older.
- You have HER2-positive breast cancer (a type that has extra HER2 protein) that is small (2 cm or less) and has not spread to lymph nodes or distant organs.
- You have not had prior treatment for this breast cancer.
- You are willing to undergo a needle biopsy before treatment to confirm the tumor type.
- You are willing to possibly skip surgery if the tumor disappears after drug treatment.
- Your overall health is good, with no serious heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
This trial tests whether some women with HER2-positive breast cancer can safely avoid breast surgery if their tumor nearly disappears after chemotherapy. It uses MRI and biopsy results to find people most likely to have no remaining cancer (pCR).
This trial tests a combination of two drugs (KN026 and HB1801) given after surgery to prevent breast cancer from coming back in people with HER2-positive breast cancer that had spread to lymph nodes. It aims to improve cure rates with a targeted approach.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of two targeted therapies given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see if this approach is safe and effective for early-stage breast cancer.
Hear when a new Mammary Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.